Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Peritoneal Neoplasms | 36 | 2024 | 710 | 6.050 |
Why?
|
Hyperthermia, Induced | 28 | 2024 | 417 | 5.000 |
Why?
|
Appendiceal Neoplasms | 22 | 2023 | 155 | 3.840 |
Why?
|
Chemotherapy, Cancer, Regional Perfusion | 15 | 2024 | 94 | 1.380 |
Why?
|
Lateral Ligament, Ankle | 2 | 2021 | 56 | 0.860 |
Why?
|
Combined Modality Therapy | 26 | 2024 | 8519 | 0.850 |
Why?
|
Palliative Care | 5 | 2022 | 3599 | 0.800 |
Why?
|
Sentinel Lymph Node Biopsy | 3 | 2016 | 732 | 0.790 |
Why?
|
Methadone | 1 | 2024 | 321 | 0.750 |
Why?
|
Adenocarcinoma, Mucinous | 4 | 2022 | 517 | 0.720 |
Why?
|
Carcinoid Tumor | 2 | 2019 | 225 | 0.680 |
Why?
|
Talus | 1 | 2020 | 86 | 0.660 |
Why?
|
Fluid Therapy | 2 | 2019 | 578 | 0.600 |
Why?
|
Intestinal Obstruction | 1 | 2021 | 432 | 0.570 |
Why?
|
Euthanasia | 1 | 2017 | 58 | 0.560 |
Why?
|
Colorectal Neoplasms | 12 | 2024 | 6919 | 0.560 |
Why?
|
Suicide, Assisted | 1 | 2017 | 68 | 0.550 |
Why?
|
Pseudomyxoma Peritonei | 3 | 2021 | 21 | 0.550 |
Why?
|
Methylene Blue | 1 | 2016 | 155 | 0.520 |
Why?
|
Body Temperature | 1 | 2019 | 780 | 0.520 |
Why?
|
Survival Rate | 25 | 2024 | 12728 | 0.510 |
Why?
|
Carcinoma | 3 | 2015 | 2330 | 0.490 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 19 | 2024 | 11733 | 0.470 |
Why?
|
Coloring Agents | 1 | 2016 | 561 | 0.450 |
Why?
|
Pain, Postoperative | 1 | 2024 | 1741 | 0.430 |
Why?
|
Cystadenoma, Mucinous | 1 | 2013 | 62 | 0.430 |
Why?
|
Intraoperative Care | 3 | 2024 | 767 | 0.430 |
Why?
|
Length of Stay | 2 | 2024 | 6417 | 0.400 |
Why?
|
Mesothelioma, Cystic | 1 | 2011 | 4 | 0.380 |
Why?
|
Mitomycin | 2 | 2009 | 263 | 0.370 |
Why?
|
Appendectomy | 1 | 2013 | 434 | 0.340 |
Why?
|
Fibula | 2 | 2021 | 266 | 0.300 |
Why?
|
Postoperative Complications | 8 | 2020 | 15637 | 0.300 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2009 | 677 | 0.300 |
Why?
|
Retrospective Studies | 36 | 2024 | 80674 | 0.300 |
Why?
|
Lymphatic Metastasis | 4 | 2022 | 2913 | 0.300 |
Why?
|
Antineoplastic Agents | 6 | 2019 | 13632 | 0.290 |
Why?
|
Analgesics, Opioid | 1 | 2024 | 3805 | 0.290 |
Why?
|
Infusions, Parenteral | 4 | 2015 | 398 | 0.290 |
Why?
|
Communication | 1 | 2022 | 3872 | 0.290 |
Why?
|
Preoperative Care | 4 | 2020 | 2241 | 0.280 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2011 | 592 | 0.280 |
Why?
|
Hepatectomy | 2 | 2020 | 557 | 0.270 |
Why?
|
Prognosis | 16 | 2024 | 29687 | 0.270 |
Why?
|
Appendicitis | 1 | 2013 | 676 | 0.270 |
Why?
|
Ankle Joint | 2 | 2021 | 446 | 0.270 |
Why?
|
Cyclin E | 1 | 2007 | 156 | 0.270 |
Why?
|
Quality of Life | 2 | 2018 | 13367 | 0.270 |
Why?
|
Patient Selection | 4 | 2022 | 4246 | 0.250 |
Why?
|
Nomograms | 1 | 2007 | 230 | 0.250 |
Why?
|
Multiple Endocrine Neoplasia Type 1 | 1 | 2005 | 43 | 0.240 |
Why?
|
Purines | 1 | 2008 | 609 | 0.240 |
Why?
|
Injections, Intraperitoneal | 4 | 2015 | 413 | 0.240 |
Why?
|
Gift Giving | 1 | 2005 | 76 | 0.230 |
Why?
|
Neutropenia | 1 | 2009 | 885 | 0.220 |
Why?
|
Humans | 69 | 2024 | 761208 | 0.220 |
Why?
|
Hyperparathyroidism | 1 | 2005 | 337 | 0.220 |
Why?
|
Therapeutic Irrigation | 1 | 2024 | 293 | 0.210 |
Why?
|
Doxorubicin | 1 | 2008 | 2224 | 0.190 |
Why?
|
Neoplasms, Experimental | 1 | 2007 | 1225 | 0.190 |
Why?
|
Sarcoma | 2 | 2010 | 1800 | 0.180 |
Why?
|
Analgesia, Epidural | 1 | 2024 | 332 | 0.180 |
Why?
|
Autophagy | 1 | 2008 | 1327 | 0.180 |
Why?
|
Appendix | 1 | 2021 | 109 | 0.170 |
Why?
|
Middle Aged | 30 | 2024 | 220853 | 0.170 |
Why?
|
Conflict of Interest | 1 | 2005 | 554 | 0.170 |
Why?
|
Intra-Articular Fractures | 1 | 2020 | 72 | 0.170 |
Why?
|
Mesothelioma | 3 | 2020 | 807 | 0.160 |
Why?
|
Epidural Abscess | 1 | 2020 | 94 | 0.160 |
Why?
|
Ascites | 1 | 2021 | 338 | 0.160 |
Why?
|
Calcaneus | 1 | 2020 | 142 | 0.160 |
Why?
|
Follow-Up Studies | 10 | 2024 | 39126 | 0.160 |
Why?
|
Carcinoma, Signet Ring Cell | 1 | 2019 | 82 | 0.160 |
Why?
|
Neoplasms | 5 | 2020 | 22140 | 0.160 |
Why?
|
Cell Cycle | 1 | 2007 | 2925 | 0.150 |
Why?
|
Drug Industry | 1 | 2005 | 788 | 0.150 |
Why?
|
Female | 37 | 2024 | 392544 | 0.150 |
Why?
|
Morals | 1 | 2021 | 289 | 0.150 |
Why?
|
Abdominal Neoplasms | 1 | 2019 | 287 | 0.150 |
Why?
|
Melanoma | 1 | 2016 | 5694 | 0.150 |
Why?
|
Disease Management | 2 | 2018 | 2507 | 0.140 |
Why?
|
Adenocarcinoma | 3 | 2022 | 6341 | 0.140 |
Why?
|
Medical Assistance | 1 | 2017 | 108 | 0.140 |
Why?
|
Skin Neoplasms | 1 | 2016 | 5809 | 0.140 |
Why?
|
Osteomyelitis | 1 | 2020 | 407 | 0.130 |
Why?
|
Ankle Injuries | 1 | 2021 | 338 | 0.130 |
Why?
|
Male | 30 | 2024 | 360693 | 0.130 |
Why?
|
Treatment Outcome | 11 | 2021 | 64681 | 0.130 |
Why?
|
Anastomosis, Surgical | 1 | 2019 | 982 | 0.130 |
Why?
|
Lymph Nodes | 1 | 2007 | 3461 | 0.130 |
Why?
|
Breast Neoplasms | 4 | 2013 | 20982 | 0.130 |
Why?
|
Aged | 20 | 2024 | 169288 | 0.130 |
Why?
|
Tumor Suppressor Protein p14ARF | 1 | 2015 | 84 | 0.120 |
Why?
|
Osteotomy | 1 | 2020 | 836 | 0.120 |
Why?
|
Physicians | 2 | 2021 | 4584 | 0.120 |
Why?
|
Tibia | 1 | 2021 | 1070 | 0.120 |
Why?
|
Anesthesia, Spinal | 2 | 1996 | 279 | 0.120 |
Why?
|
Genes, p16 | 1 | 2015 | 160 | 0.120 |
Why?
|
Neural Conduction | 2 | 2004 | 441 | 0.120 |
Why?
|
Tetracaine | 1 | 1994 | 34 | 0.120 |
Why?
|
Postoperative Care | 1 | 2020 | 1468 | 0.110 |
Why?
|
Fracture Fixation, Internal | 1 | 2020 | 971 | 0.110 |
Why?
|
Colonic Neoplasms | 2 | 2019 | 2527 | 0.110 |
Why?
|
Morbidity | 1 | 2018 | 1751 | 0.110 |
Why?
|
ROC Curve | 3 | 2022 | 3584 | 0.110 |
Why?
|
Patient Transfer | 1 | 2020 | 794 | 0.110 |
Why?
|
Lidocaine | 2 | 1996 | 538 | 0.100 |
Why?
|
Mucins | 2 | 2023 | 569 | 0.100 |
Why?
|
Bupivacaine | 2 | 1996 | 411 | 0.100 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2007 | 5300 | 0.100 |
Why?
|
Nurses | 1 | 2021 | 2477 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3512 | 0.090 |
Why?
|
Sciatic Nerve | 1 | 1994 | 618 | 0.090 |
Why?
|
Lymph Node Excision | 2 | 2007 | 1270 | 0.090 |
Why?
|
Tumor Cells, Cultured | 2 | 2008 | 6124 | 0.090 |
Why?
|
Neoplasm Staging | 5 | 2023 | 11119 | 0.080 |
Why?
|
Patient Readmission | 2 | 2023 | 3265 | 0.080 |
Why?
|
Tumor Stem Cell Assay | 1 | 2008 | 115 | 0.080 |
Why?
|
Guideline Adherence | 1 | 2019 | 2220 | 0.080 |
Why?
|
Referral and Consultation | 1 | 2022 | 3608 | 0.080 |
Why?
|
Critical Care | 1 | 2021 | 2696 | 0.080 |
Why?
|
G2 Phase | 1 | 2008 | 136 | 0.080 |
Why?
|
Fractures, Bone | 1 | 2020 | 2046 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2018 | 2915 | 0.080 |
Why?
|
Cytotoxins | 1 | 2008 | 153 | 0.070 |
Why?
|
Artificial Intelligence | 1 | 2022 | 2576 | 0.070 |
Why?
|
Nerve Block | 1 | 1994 | 706 | 0.070 |
Why?
|
Predictive Value of Tests | 4 | 2019 | 15308 | 0.070 |
Why?
|
Mucin-2 | 1 | 2007 | 50 | 0.070 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2010 | 333 | 0.070 |
Why?
|
Delphi Technique | 2 | 2020 | 848 | 0.070 |
Why?
|
Terminal Care | 1 | 2017 | 1760 | 0.060 |
Why?
|
Algorithms | 1 | 2006 | 14025 | 0.060 |
Why?
|
Risk Factors | 7 | 2020 | 74239 | 0.060 |
Why?
|
Adult | 11 | 2021 | 221119 | 0.060 |
Why?
|
Swine | 1 | 2014 | 5909 | 0.060 |
Why?
|
Drug Synergism | 1 | 2008 | 1756 | 0.060 |
Why?
|
Apoptosis | 3 | 2015 | 9477 | 0.060 |
Why?
|
Liver Neoplasms | 1 | 2000 | 4309 | 0.060 |
Why?
|
Incidence | 2 | 2013 | 21365 | 0.050 |
Why?
|
Area Under Curve | 1 | 2007 | 1636 | 0.050 |
Why?
|
Parathyroidectomy | 1 | 2005 | 242 | 0.050 |
Why?
|
Marketing | 1 | 2005 | 220 | 0.050 |
Why?
|
United States | 8 | 2020 | 72339 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2020 | 9278 | 0.050 |
Why?
|
Tumor Burden | 1 | 2007 | 1892 | 0.050 |
Why?
|
Heel | 1 | 2020 | 38 | 0.050 |
Why?
|
Survival Analysis | 3 | 2020 | 10088 | 0.040 |
Why?
|
Anesthetics, Local | 2 | 2004 | 998 | 0.040 |
Why?
|
Aged, 80 and over | 3 | 2019 | 58952 | 0.040 |
Why?
|
Patient Discharge | 2 | 2023 | 3441 | 0.040 |
Why?
|
Interprofessional Relations | 1 | 2005 | 990 | 0.040 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2004 | 709 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2007 | 3592 | 0.040 |
Why?
|
Lung Diseases, Interstitial | 1 | 2007 | 918 | 0.040 |
Why?
|
Biology | 1 | 2020 | 290 | 0.040 |
Why?
|
Databases, Factual | 2 | 2019 | 7966 | 0.040 |
Why?
|
Preoperative Period | 1 | 2019 | 551 | 0.040 |
Why?
|
Age Factors | 1 | 2013 | 18384 | 0.030 |
Why?
|
Cadaver | 1 | 2021 | 1358 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2007 | 4909 | 0.030 |
Why?
|
Neoadjuvant Therapy | 1 | 2007 | 2827 | 0.030 |
Why?
|
Postoperative Period | 1 | 2020 | 1818 | 0.030 |
Why?
|
Cohort Studies | 4 | 2021 | 41496 | 0.030 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2019 | 487 | 0.030 |
Why?
|
Biopsy | 1 | 2007 | 6781 | 0.030 |
Why?
|
Young Adult | 3 | 2021 | 59221 | 0.030 |
Why?
|
Rana catesbeiana | 1 | 1994 | 85 | 0.030 |
Why?
|
Radiculopathy | 1 | 1996 | 201 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 899 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2021 | 1303 | 0.030 |
Why?
|
Mutation | 1 | 2018 | 30002 | 0.030 |
Why?
|
Animals | 5 | 2015 | 168079 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2007 | 12052 | 0.030 |
Why?
|
beta Catenin | 1 | 2018 | 1042 | 0.030 |
Why?
|
Joint Instability | 1 | 2021 | 801 | 0.030 |
Why?
|
Aftercare | 1 | 2019 | 913 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 3 | 2021 | 20588 | 0.030 |
Why?
|
Perioperative Care | 1 | 2020 | 1037 | 0.030 |
Why?
|
Models, Biological | 1 | 2008 | 9457 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2007 | 12976 | 0.020 |
Why?
|
Asthma | 1 | 2011 | 6230 | 0.020 |
Why?
|
Decision Making | 1 | 2006 | 3931 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2007 | 14675 | 0.020 |
Why?
|
Adolescent | 2 | 2013 | 88298 | 0.020 |
Why?
|
Insurance Coverage | 1 | 2022 | 1935 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2015 | 2010 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 3590 | 0.020 |
Why?
|
Lumbar Vertebrae | 1 | 2020 | 1876 | 0.020 |
Why?
|
Hypertension | 1 | 2011 | 8536 | 0.020 |
Why?
|
Adenoviridae | 1 | 2015 | 1084 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1746 | 0.020 |
Why?
|
Random Allocation | 1 | 2015 | 2393 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 2007 | 4872 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4107 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2007 | 20119 | 0.020 |
Why?
|
Population Surveillance | 1 | 2019 | 2598 | 0.020 |
Why?
|
Mice, Nude | 1 | 2015 | 3605 | 0.020 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2019 | 2787 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2007 | 18220 | 0.020 |
Why?
|
Logistic Models | 1 | 2022 | 13249 | 0.020 |
Why?
|
Disease Progression | 1 | 2024 | 13511 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2020 | 5295 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2019 | 5493 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2018 | 3634 | 0.020 |
Why?
|
Time Factors | 2 | 2000 | 39957 | 0.020 |
Why?
|
Analysis of Variance | 1 | 1994 | 6223 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2015 | 3388 | 0.020 |
Why?
|
SEER Program | 1 | 2010 | 1453 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2010 | 1784 | 0.010 |
Why?
|
Detergents | 1 | 2004 | 235 | 0.010 |
Why?
|
Registries | 1 | 2019 | 8247 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1994 | 10756 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7400 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2010 | 6819 | 0.010 |
Why?
|
Risk Assessment | 1 | 2020 | 24021 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2015 | 16952 | 0.010 |
Why?
|
Cell Membrane | 1 | 2004 | 3661 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2013 | 5366 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 5321 | 0.010 |
Why?
|
Rats | 1 | 2004 | 23704 | 0.000 |
Why?
|
Mice | 1 | 2015 | 81326 | 0.000 |
Why?
|
Neurons | 1 | 2004 | 9428 | 0.000 |
Why?
|
Concepts
(223)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(5)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_